View source for 9bjm


==Crystal Structure of Inhibitor 5c in Complex with Prefusion RSV F Glycoprotein==
<StructureSection load='9bjm' size='340' side='right'caption='[[9bjm]], [[Resolution|resolution]] 2.07&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[9bjm]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1] and [https://en.wikipedia.org/wiki/Human_orthopneumovirus Human orthopneumovirus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9BJM OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9BJM FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.07&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A1APZ:1-{[5-chloro-1-(4,4,4-trifluorobutyl)-1H-1,3-benzimidazol-2-yl]methyl}-1-(methanesulfonyl)spiro[azetidine-3,3-indol]-2(1H)-one'>A1APZ</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9bjm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9bjm OCA], [https://pdbe.org/9bjm PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9bjm RCSB], [https://www.ebi.ac.uk/pdbsum/9bjm PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9bjm ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/M1E1E4_9HIV1 M1E1E4_9HIV1] [https://www.uniprot.org/uniprot/W8RJF9_HRSV W8RJF9_HRSV] 
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants, the elderly, and immune-compromised patients. While a half-life extended monoclonal antibody and 2 vaccines have recently been approved for infants and the elderly, respectively, options to prevent disease in immune-compromised patients are still needed. Here, we describe spiro-azetidine oxindoles as small molecule RSV entry inhibitors displaying favorable potency, developability attributes, and long-acting PK when injected as an aqueous suspension, suggesting their potential to prevent complications following RSV infection over a period of 3 to 6 months with 1 or 2 long-acting intramuscular (IM) or subcutaneous (SC) injections in these immune-compromised patients.

Spiro-Azetidine Oxindoles as Long-Acting Injectables for Pre-Exposure Prophylaxis against Respiratory Syncytial Virus Infections.,Kesteleyn B, Herschke F, Darville N, Stoops B, Jacobs T, Jacoby E, Shaffer P, Lammens L, Van Rompaey D, Matcha K, Martinez Lamenca C, Coesemans E, Hache G, Pieters S, Lecomte M, Hu L, Demin S, Milligan C, Abeywickrema P, De Bruyn S, Van Den Berg J, Ysebaert N, De Zwart L, Najera I, Rigaux P, Roymans D, Jonckers THM J Med Chem. 2024 Jul 11;67(13):10986-11002. doi: 10.1021/acs.jmedchem.4c00514. , Epub 2024 Jun 26. PMID:38932487<ref>PMID:38932487</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 9bjm" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Human immunodeficiency virus 1]]
[[Category: Human orthopneumovirus]]
[[Category: Large Structures]]
[[Category: Abeywickrema P]]
[[Category: Milligan C]]
[[Category: Shaffer PL]]